GSK Signs an Agreement with Immatics to Develop Adoptive Cell Therapies for Multiple Cancer Indications

 GSK Signs an Agreement with Immatics to Develop Adoptive Cell Therapies for Multiple Cancer Indications

GSK Signs an Agreement with Immatics to Develop Adoptive Cell Therapies for Multiple Cancer Indications

Shots:

  • Immatics to receive ~$50M up front for two initial programs & ~$550M as milestones/ product along with royalties. Immatics is eligible to receive option, milestones and royalties on each additional program
  • GSK to get access to two Immatic’s TCR-T programs and will get an option to select additional targets to include in the collaboration. The collaboration will initially focus on developing autologous T-cell therapies with an option to add allogeneic cell therapies using Immatics’ ACTallo approach
  • Immatics will be responsible for the development of TCR therapies up to clinical, later GSK will be responsible for further development & commercialization. The companies may co-develop one or more TCR therapies including the conduction of first-in-human clinical studies

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Immatics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post